Webinars » Therapeutic Antibody » Webinar - Design. Build. Scale: AAV Discovery to Process Development

Webinar - Design. Build. Scale: AAV Discovery to Process Development

Adeno-associated viruses (AAVs) are widely used in gene therapy for its safety and ability to support long-term gene expression. Join us to gain integrated insights across AAV development—from vector discovery and plasmid design to process development.

  • Cheng Luo

    Cheng Luo
    Director of Pharmacology Dept., ProBio

  • Luffy Chen

    Luffy Chen
    Head of Plasmid PD and Production Dept., ProBio

  • Xiyang Wang

    Xiyang Wang
    Sr. Researcher, Viral Vector PD Dept. ProBio

Time Topic
14:00-14:45 One-stop AAV Drug Discovery Solution, from DNA to PCC
Cheng Luo, Director of Pharmacology Dept., ProBio
  • From plasmid design to AAV packaging and in vitro/in vivo assays
  • GOI validation: assessing transduction efficiency, bioactivity, and safety
  • Preclinical candidate (PCC) screening
14:45-15:30 AAV Plasmid Production: Key Challenges and Control Strategies
Luffy Chen, Head of Plasmid PD and Production Dept., ProBio
  • Key challenges in AAV plasmid production
  • Robust processes with proprietary strains for AAV plasmid
  • Insights into industry trends, challenges, and opportunities
15:30-16:15 AAV Overview and Solutions in Cell and Gene Therapy
Xiyang Wang, Sr. Researcher, Viral Vector PD Dept., ProBio
  • Overview of AAV and applications in CGT
  • Challenges in AAV vector process development and production
  • Innovative solutions with the ProBio process platform and case study

Related service: AAV Drug Discovery, AAssistV™ Plasmid, AAV CDMO

Available materials

«
Previous Page
ProBio Announces New Executive Appointments
Next Page
ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy
»
  • Contact us
  • Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188
  • Fax: 1-732-210-0262